Last Updated: June 22, 2026

HYDROMORPHONE Drug Patent Profile

Name: HYDROMORPHONE Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Hydromorphone, and what generic alternatives are available?

Hydromorphone is a drug marketed by Barr, Hikma, Hospira, Hospira Inc, Rising, Watson Labs, Ascent Pharms Inc, Genus, Actavis Labs Fl Inc, Osmotica Pharm Us, Padagis Us, Aurolife Pharma Llc, Mpp Pharma, Nesher Pharms, and Specgx Llc. and is included in twenty-four NDAs.

The generic ingredient in HYDROMORPHONE is hydromorphone hydrochloride. There are fourteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the hydromorphone hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Hydromorphone

A generic version of HYDROMORPHONE was approved as hydromorphone hydrochloride by HIKMA on July 29^th, 1998.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for HYDROMORPHONE?
What are the global sales for HYDROMORPHONE?
What is Average Wholesale Price for HYDROMORPHONE?

Summary for HYDROMORPHONE

US Patents:	0
Applicants:	15
NDAs:	24
Drug Prices:	Drug price information for HYDROMORPHONE
Drug Sales Revenues:	Drug sales revenues for HYDROMORPHONE
DailyMed Link:	HYDROMORPHONE at DailyMed

Drug patent expirations by year for HYDROMORPHONE

US Patents and Regulatory Information for HYDROMORPHONE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurolife Pharma Llc	HYDROMORPHONE HYDROCHLORIDE	hydromorphone hydrochloride	TABLET;ORAL	205814-001	May 13, 2016	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Osmotica Pharm Us	HYDROMORPHONE HYDROCHLORIDE	hydromorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205629-005	Oct 30, 2024		RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Mpp Pharma	HYDROMORPHONE HYDROCHLORIDE	hydromorphone hydrochloride	TABLET;ORAL	076723-001	Oct 18, 2005		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Genus	HYDROMORPHONE HYDROCHLORIDE	hydromorphone hydrochloride	TABLET;ORAL	077471-003	Dec 9, 2009		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

DrugChatter Q&A for HYDROMORPHONE

Hydromorphone for shortness of breath?

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.